TerraPower and Cardinal Health announce manufacturing and distribution agreement for Actinium-225

08/12/2021

Cardinal Health is pleased to announce an agreement with TerraPower that will help advance the next generation of cancer treatment. Working together, the companies will develop and produce Actinium-225, which will be utilized in drug trials involving targeted alpha therapy for diseases such as breast, prostate, colon and neuroendocrine cancers, melanoma and lymphoma.

Tags: < Partnership

TerraPower and Cardinal Health announce manufacturing and distribution agreement for Actinium-225

Related Industries

Johnson & Johnson Opens State-of-the-Art Science and Technology Campus in San Francisco Bay Area

GE Healthcare showcases innovations designed to build cardiology care of the future at TCT2022

GE Announces Board of Directors for Future Independent GE HealthCare; Confirms Target Spin-Off Timing of First Week of January 2023

BD Appoints Two Business Unit Presidents

Honeywell To Collaborate With Leading Health Providers To Advance Digitalization Of Healthcare Globally

DSM completes acquisition of Prodap

Schneider Electric Appoints Dallas-based Joshua Dickinson as SVP and CFO for North America Region

Hertz, bp collaborate to accelerate EV charging in North America

Macy’s, Inc. Names Pam Quintiliano Head of Investor Relations

Billionaire Philanthropist Robert F. Smith to Keynote HP’s HBCU Tech Conference

Marriott International Debuts Its New Global Headquarters, Unveiling Technology and Design for an Intuitive Workplace

Ford Motor Company Partners with Climate Museum to Call Attention to Impacts of Climate Change Through Live Art Installation

GE Announces Board of Directors for Future Independent GE HealthCare; Confirms Target Spin-Off Timing of First Week of January 2023

GM Investing $760 Million in Toledo, Ohio Propulsion Plant for EV Drive Unit Production

Intel Launches 13th Gen Intel Core Processor Family Alongside New Intel Unison Solution

INDUSTRIES

CONTACT US